AstraZeneca sues Innopharma for patent infringement
AstraZeneca has sued Innopharma over its attempt to market a generic version of breast cancer treatment drug Faslodex (fulvestrant).
In a lawsuit filed at the US District Court for the District of New Jersey last week, AstraZeneca took issue with Innopharma’s Abbreviated New Drug Application (ANDA).
Innopharma notified AstraZeneca of its ANDA on January 25, 2016. The complaint was filed on February 16.
AstraZeneca claimed the generic would infringe four patents covering the drug, all of which expire in 2021.
Faslodex is a hormonal therapy drug prescribed to women with breast cancer who have gone through the menopause.
In its complaint, AstraZeneca requested that Judge Renee Marie Bumb be assigned to the case.
In December, Bumb consolidated several cases filed by AstraZeneca against generic companies including Sandoz and Mylan, all of which had sought to market a generic version of the drug.
